Alvotech (NASDAQ: ALVOW) Stock Competitors & Peer Comparison
See ALVOW's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ALVOW and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ALVOW | $0.22 | +9.07% | 2B | 32.08 | $0.01 | N/A |
| TAK | $18.18 | +0.28% | 57.9B | 13.07 | $1.39 | +3.47% |
| HLN | $10.00 | +1.32% | 44.1B | 18.66 | $0.54 | +1.24% |
| TEVA | $37.34 | +1.44% | 43.5B | 12.74 | $2.93 | N/A |
| ZTS | $77.73 | +3.61% | 32.6B | 11.81 | $6.58 | +2.69% |
| VTRS | $16.32 | +1.24% | 19B | 6.48 | $2.52 | +2.94% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.97 | +1.74% | 12B | 22.62 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $12.18 | +0.58% | 10.2B | 19.98 | $0.61 | +0.68% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
ALVOW vs TAK Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, TAK has a market cap of 57.9B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while TAK trades at $18.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas TAK's P/E ratio is 13.07. In terms of profitability, ALVOW's ROE is +0.77%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ALVOW is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check TAK's competition here
Haleon plc (NYSE: HLN)
ALVOW vs HLN Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, HLN has a market cap of 44.1B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while HLN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas HLN's P/E ratio is 18.66. In terms of profitability, ALVOW's ROE is +0.77%, compared to HLN's ROE of +0.17%. Regarding short-term risk, ALVOW is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
ALVOW vs TEVA Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, TEVA has a market cap of 43.5B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while TEVA trades at $37.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas TEVA's P/E ratio is 12.74. In terms of profitability, ALVOW's ROE is +0.77%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, ALVOW is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check TEVA's competition here
Zoetis Inc. (NYSE: ZTS)
ALVOW vs ZTS Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, ZTS has a market cap of 32.6B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while ZTS trades at $77.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas ZTS's P/E ratio is 11.81. In terms of profitability, ALVOW's ROE is +0.77%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, ALVOW is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
ALVOW vs VTRS Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, VTRS has a market cap of 19B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while VTRS trades at $16.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas VTRS's P/E ratio is 6.48. In terms of profitability, ALVOW's ROE is +0.77%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, ALVOW is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
ALVOW vs ITCI Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ALVOW's ROE is +0.77%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ALVOW is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
ALVOW vs ELAN Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, ELAN has a market cap of 12B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while ELAN trades at $23.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas ELAN's P/E ratio is 22.62. In terms of profitability, ALVOW's ROE is +0.77%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, ALVOW is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
ALVOW vs CTLT Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ALVOW's ROE is +0.77%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ALVOW is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
ALVOW vs RDY Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, RDY has a market cap of 10.2B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while RDY trades at $12.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas RDY's P/E ratio is 19.98. In terms of profitability, ALVOW's ROE is +0.77%, compared to RDY's ROE of +0.09%. Regarding short-term risk, ALVOW is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
ALVOW vs LNTH Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while LNTH trades at $99.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas LNTH's P/E ratio is 16.80. In terms of profitability, ALVOW's ROE is +0.77%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ALVOW is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
ALVOW vs AMRX Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, AMRX has a market cap of 5.7B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while AMRX trades at $17.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas AMRX's P/E ratio is 19.90. In terms of profitability, ALVOW's ROE is +0.77%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, ALVOW is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
ALVOW vs INDV Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, INDV has a market cap of 4.6B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while INDV trades at $36.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas INDV's P/E ratio is 10.10. In terms of profitability, ALVOW's ROE is +0.77%, compared to INDV's ROE of -2.16%. Regarding short-term risk, ALVOW is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
ALVOW vs SUPN Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, SUPN has a market cap of 2.7B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while SUPN trades at $45.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas SUPN's P/E ratio is 14.98. In terms of profitability, ALVOW's ROE is +0.77%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, ALVOW is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
ALVOW vs RGC Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, RGC has a market cap of 2.6B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while RGC trades at $5.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas RGC's P/E ratio is -373.24. In terms of profitability, ALVOW's ROE is +0.77%, compared to RGC's ROE of -2.32%. Regarding short-term risk, ALVOW is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
ALVOW vs BHC Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while BHC trades at $6.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas BHC's P/E ratio is 1.64. In terms of profitability, ALVOW's ROE is +0.77%, compared to BHC's ROE of +0.89%. Regarding short-term risk, ALVOW is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
ALVOW vs DCPH Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ALVOW's ROE is +0.77%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ALVOW is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
ALVOW vs HCM Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while HCM trades at $12.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas HCM's P/E ratio is 4.73. In terms of profitability, ALVOW's ROE is +0.77%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ALVOW is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
ALVOW vs AVDL Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ALVOW's ROE is +0.77%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, ALVOW is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check AVDL's competition here
Perrigo Company plc (NYSE: PRGO)
ALVOW vs PRGO Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, PRGO has a market cap of 2B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while PRGO trades at $14.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas PRGO's P/E ratio is 5.70. In terms of profitability, ALVOW's ROE is +0.77%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, ALVOW is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check PRGO's competition here
Embecta Corp. (NASDAQ: EMBCV)
ALVOW vs EMBCV Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ALVOW's ROE is +0.77%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ALVOW is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check EMBCV's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
ALVOW vs TRLV Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, TRLV has a market cap of 1.9B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while TRLV trades at $11.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas TRLV's P/E ratio is -4.51. In terms of profitability, ALVOW's ROE is +0.77%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, ALVOW is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check TRLV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
ALVOW vs DVAX Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ALVOW's ROE is +0.77%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ALVOW is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check DVAX's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
ALVOW vs ETON Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, ETON has a market cap of 1.7B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while ETON trades at $63.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas ETON's P/E ratio is -906.71. In terms of profitability, ALVOW's ROE is +0.77%, compared to ETON's ROE of +0.40%. Regarding short-term risk, ALVOW is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ETON's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
ALVOW vs ANIP Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while ANIP trades at $75.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas ANIP's P/E ratio is 9.17. In terms of profitability, ALVOW's ROE is +0.77%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, ALVOW is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
ALVOW vs TARO Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas TARO's P/E ratio is 30.05. In terms of profitability, ALVOW's ROE is +0.77%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ALVOW is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
ALVOW vs HROW Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while HROW trades at $40.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas HROW's P/E ratio is -41.36. In terms of profitability, ALVOW's ROE is +0.77%, compared to HROW's ROE of -1.04%. Regarding short-term risk, ALVOW is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check HROW's competition here
Alvotech (NASDAQ: ALVO)
ALVOW vs ALVO Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, ALVO has a market cap of 1.5B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while ALVO trades at $4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas ALVO's P/E ratio is -13.03. In terms of profitability, ALVOW's ROE is +0.77%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, ALVOW is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ALVO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
ALVOW vs PAHC Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, PAHC has a market cap of 1.5B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while PAHC trades at $36.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas PAHC's P/E ratio is 12.40. In terms of profitability, ALVOW's ROE is +0.77%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, ALVOW is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
ALVOW vs CRON Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while CRON trades at $3.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas CRON's P/E ratio is 30.58. In terms of profitability, ALVOW's ROE is +0.77%, compared to CRON's ROE of +0.06%. Regarding short-term risk, ALVOW is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
ALVOW vs PCRX Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, PCRX has a market cap of 970.4M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while PCRX trades at $24.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas PCRX's P/E ratio is 9.49. In terms of profitability, ALVOW's ROE is +0.77%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, ALVOW is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check PCRX's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
ALVOW vs AMPH Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, AMPH has a market cap of 952.4M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while AMPH trades at $21.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas AMPH's P/E ratio is 7.37. In terms of profitability, ALVOW's ROE is +0.77%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, ALVOW is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check AMPH's competition here
PetIQ, Inc. (NASDAQ: PETQ)
ALVOW vs PETQ Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ALVOW's ROE is +0.77%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ALVOW is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
ALVOW vs COLL Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, COLL has a market cap of 893.2M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while COLL trades at $27.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas COLL's P/E ratio is 3.46. In terms of profitability, ALVOW's ROE is +0.77%, compared to COLL's ROE of +0.16%. Regarding short-term risk, ALVOW is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
ALVOW vs IRWD Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, IRWD has a market cap of 706.2M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while IRWD trades at $4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas IRWD's P/E ratio is 5.50. In terms of profitability, ALVOW's ROE is +0.77%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, ALVOW is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
ALVOW vs EVO Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, EVO has a market cap of 685.6M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while EVO trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas EVO's P/E ratio is -2.73. In terms of profitability, ALVOW's ROE is +0.77%, compared to EVO's ROE of -0.27%. Regarding short-term risk, ALVOW is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check EVO's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
ALVOW vs AQST Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, AQST has a market cap of 584.7M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while AQST trades at $4.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas AQST's P/E ratio is -7.64. In terms of profitability, ALVOW's ROE is +0.77%, compared to AQST's ROE of +2.44%. Regarding short-term risk, ALVOW is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check AQST's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
ALVOW vs BDSI Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ALVOW's ROE is +0.77%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ALVOW is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check BDSI's competition here
Evolus, Inc. (NASDAQ: EOLS)
ALVOW vs EOLS Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, EOLS has a market cap of 552.5M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while EOLS trades at $8.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas EOLS's P/E ratio is -26.57. In terms of profitability, ALVOW's ROE is +0.77%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, ALVOW is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check EOLS's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
ALVOW vs TLRY Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, TLRY has a market cap of 541.3M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while TLRY trades at $4.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas TLRY's P/E ratio is -4.46. In terms of profitability, ALVOW's ROE is +0.77%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, ALVOW is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
ALVOW vs KMDA Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, KMDA has a market cap of 475.4M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while KMDA trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas KMDA's P/E ratio is 21.68. In terms of profitability, ALVOW's ROE is +0.77%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ALVOW is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
ALVOW vs CGC Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, CGC has a market cap of 443.3M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while CGC trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas CGC's P/E ratio is -0.63. In terms of profitability, ALVOW's ROE is +0.77%, compared to CGC's ROE of -0.33%. Regarding short-term risk, ALVOW is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
ALVOW vs TKNO Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, TKNO has a market cap of 394.6M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while TKNO trades at $7.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas TKNO's P/E ratio is -23.74. In terms of profitability, ALVOW's ROE is +0.77%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ALVOW is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
ALVOW vs ALIM Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ALVOW's ROE is +0.77%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ALVOW is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
ALVOW vs LNDC Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ALVOW's ROE is +0.77%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, ALVOW is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check LNDC's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
ALVOW vs EBS Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, EBS has a market cap of 262.4M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while EBS trades at $5.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas EBS's P/E ratio is 3.53. In terms of profitability, ALVOW's ROE is +0.77%, compared to EBS's ROE of -0.36%. Regarding short-term risk, ALVOW is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check EBS's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
ALVOW vs ACB Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, ACB has a market cap of 244.1M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while ACB trades at $3.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas ACB's P/E ratio is -8.04. In terms of profitability, ALVOW's ROE is +0.77%, compared to ACB's ROE of -0.21%. Regarding short-term risk, ALVOW is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ACB's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
ALVOW vs ORGO Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, ORGO has a market cap of 231.6M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while ORGO trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas ORGO's P/E ratio is 60.00. In terms of profitability, ALVOW's ROE is +0.77%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, ALVOW is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
ALVOW vs TYHT Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ALVOW's ROE is +0.77%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ALVOW is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
ALVOW vs SIGA Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, SIGA has a market cap of 218M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while SIGA trades at $3.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas SIGA's P/E ratio is 11.26. In terms of profitability, ALVOW's ROE is +0.77%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, ALVOW is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check SIGA's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
ALVOW vs CRDL Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, CRDL has a market cap of 217.3M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while CRDL trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas CRDL's P/E ratio is -7.51. In terms of profitability, ALVOW's ROE is +0.77%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, ALVOW is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check CRDL's competition here
Journey Medical Corporation (NASDAQ: DERM)
ALVOW vs DERM Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, DERM has a market cap of 213.3M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while DERM trades at $7.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas DERM's P/E ratio is -20.95. In terms of profitability, ALVOW's ROE is +0.77%, compared to DERM's ROE of -0.20%. Regarding short-term risk, ALVOW is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check DERM's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
ALVOW vs REPH Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas REPH's P/E ratio is -8.04. In terms of profitability, ALVOW's ROE is +0.77%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ALVOW is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check REPH's competition here
Organigram Global Inc. (NASDAQ: OGI)
ALVOW vs OGI Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, OGI has a market cap of 176M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while OGI trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas OGI's P/E ratio is -4.81. In terms of profitability, ALVOW's ROE is +0.77%, compared to OGI's ROE of +0.21%. Regarding short-term risk, ALVOW is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
ALVOW vs LFCR Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, LFCR has a market cap of 170.3M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while LFCR trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas LFCR's P/E ratio is -4.24. In terms of profitability, ALVOW's ROE is +0.77%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, ALVOW is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check LFCR's competition here
Theratechnologies Inc. (NASDAQ: THTX)
ALVOW vs THTX Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas THTX's P/E ratio is -28.83. In terms of profitability, ALVOW's ROE is +0.77%, compared to THTX's ROE of +0.17%. Regarding short-term risk, ALVOW is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
ALVOW vs ASRT Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas ASRT's P/E ratio is -7.10. In terms of profitability, ALVOW's ROE is +0.77%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, ALVOW is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
ALVOW vs SCTL Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ALVOW's ROE is +0.77%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ALVOW is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check SCTL's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
ALVOW vs CPIX Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, CPIX has a market cap of 112.4M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while CPIX trades at $7.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas CPIX's P/E ratio is -18.75. In terms of profitability, ALVOW's ROE is +0.77%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, ALVOW is more volatile compared to CPIX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check CPIX's competition here
Procaps Group S.A. (NASDAQ: PROC)
ALVOW vs PROC Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas PROC's P/E ratio is 1.53. In terms of profitability, ALVOW's ROE is +0.77%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ALVOW is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check PROC's competition here
BGM Group Ltd. (NASDAQ: BGM)
ALVOW vs BGM Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, BGM has a market cap of 101.1M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while BGM trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas BGM's P/E ratio is -0.92. In terms of profitability, ALVOW's ROE is +0.77%, compared to BGM's ROE of -0.07%. Regarding short-term risk, ALVOW is more volatile compared to BGM. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check BGM's competition here
OptiNose, Inc. (NASDAQ: OPTN)
ALVOW vs OPTN Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ALVOW's ROE is +0.77%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ALVOW is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check OPTN's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
ALVOW vs ZYBT Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, ZYBT has a market cap of 96.7M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while ZYBT trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas ZYBT's P/E ratio is -9.27. In terms of profitability, ALVOW's ROE is +0.77%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, ALVOW is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ZYBT's competition here
Zomedica Corp. (AMEX: ZOM)
ALVOW vs ZOM Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ALVOW's ROE is +0.77%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, ALVOW is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
ALVOW vs GRVI Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ALVOW's ROE is +0.77%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, ALVOW is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
ALVOW vs ZYNE Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ALVOW's ROE is +0.77%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ALVOW is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
ALVOW vs SSIC Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ALVOW's ROE is +0.77%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ALVOW is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check SSIC's competition here
Talphera, Inc. (NASDAQ: TLPH)
ALVOW vs TLPH Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, TLPH has a market cap of 61.8M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while TLPH trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas TLPH's P/E ratio is -3.84. In terms of profitability, ALVOW's ROE is +0.77%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, ALVOW is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check TLPH's competition here
The Valens Company Inc. (NASDAQ: VLNS)
ALVOW vs VLNS Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ALVOW's ROE is +0.77%, compared to VLNS's ROE of N/A. Regarding short-term risk, ALVOW is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
ALVOW vs DRRX Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ALVOW's ROE is +0.77%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, ALVOW is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
ALVOW vs INCR Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, INCR has a market cap of 51.5M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while INCR trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas INCR's P/E ratio is -2.01. In terms of profitability, ALVOW's ROE is +0.77%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ALVOW is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
ALVOW vs JUPW Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ALVOW's ROE is +0.77%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, ALVOW is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check JUPW's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
ALVOW vs CPHI Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, CPHI has a market cap of 42.5M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while CPHI trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas CPHI's P/E ratio is -1.64. In terms of profitability, ALVOW's ROE is +0.77%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, ALVOW is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check CPHI's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
ALVOW vs QLI Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas QLI's P/E ratio is -4.92. In terms of profitability, ALVOW's ROE is +0.77%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ALVOW is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check QLI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
ALVOW vs RMTI Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, RMTI has a market cap of 32M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while RMTI trades at $8.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas RMTI's P/E ratio is -6.04. In terms of profitability, ALVOW's ROE is +0.77%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, ALVOW is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
ALVOW vs HEXO Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ALVOW's ROE is +0.77%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ALVOW is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check HEXO's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
ALVOW vs AYTU Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, AYTU has a market cap of 25.4M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while AYTU trades at $2.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas AYTU's P/E ratio is -1.23. In terms of profitability, ALVOW's ROE is +0.77%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, ALVOW is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
ALVOW vs TXMD Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, TXMD has a market cap of 23.8M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while TXMD trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas TXMD's P/E ratio is 104.94. In terms of profitability, ALVOW's ROE is +0.77%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, ALVOW is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
ALVOW vs CYTH Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ALVOW's ROE is +0.77%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ALVOW is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
ALVOW vs EVOK Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ALVOW's ROE is +0.77%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, ALVOW is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
ALVOW vs OPTH Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, OPTH has a market cap of 16.1M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while OPTH trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas OPTH's P/E ratio is -18.30. In terms of profitability, ALVOW's ROE is +0.77%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, ALVOW is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
ALVOW vs ACRX Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ALVOW's ROE is +0.77%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, ALVOW is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
ALVOW vs CABR Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, CABR has a market cap of 12.1M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while CABR trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas CABR's P/E ratio is -2.37. In terms of profitability, ALVOW's ROE is +0.77%, compared to CABR's ROE of -3.28%. Regarding short-term risk, ALVOW is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
ALVOW vs AGRX Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ALVOW's ROE is +0.77%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ALVOW is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
ALVOW vs NLTX Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ALVOW's ROE is +0.77%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, ALVOW is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
ALVOW vs LCI Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas LCI's P/E ratio is -0.04. In terms of profitability, ALVOW's ROE is +0.77%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ALVOW is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
ALVOW vs ADMP Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ALVOW's ROE is +0.77%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ALVOW is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
ALVOW vs YCBD Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, YCBD has a market cap of 5.3M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while YCBD trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas YCBD's P/E ratio is -1.25. In terms of profitability, ALVOW's ROE is +0.77%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ALVOW is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
ALVOW vs GELS Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, GELS has a market cap of 4.9M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while GELS trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas GELS's P/E ratio is -1.07. In terms of profitability, ALVOW's ROE is +0.77%, compared to GELS's ROE of -0.25%. Regarding short-term risk, ALVOW is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
ALVOW vs MNK Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas MNK's P/E ratio is -0.44. In terms of profitability, ALVOW's ROE is +0.77%, compared to MNK's ROE of -0.36%. Regarding short-term risk, ALVOW is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
ALVOW vs FLGC Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ALVOW's ROE is +0.77%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ALVOW is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
ALVOW vs UPC Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, UPC has a market cap of 3.4M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while UPC trades at $5.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas UPC's P/E ratio is -0.68. In terms of profitability, ALVOW's ROE is +0.77%, compared to UPC's ROE of -0.03%. Regarding short-term risk, ALVOW is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
ALVOW vs SBFM Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, SBFM has a market cap of 2.8M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while SBFM trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas SBFM's P/E ratio is -0.19. In terms of profitability, ALVOW's ROE is +0.77%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, ALVOW is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
ALVOW vs PLXP Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ALVOW's ROE is +0.77%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ALVOW is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
ALVOW vs ATNX Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ALVOW's ROE is +0.77%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ALVOW is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ATNX's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
ALVOW vs SHPH Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, SHPH has a market cap of 2.3M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while SHPH trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas SHPH's P/E ratio is -0.18. In terms of profitability, ALVOW's ROE is +0.77%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, ALVOW is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check SHPH's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
ALVOW vs SNOA Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, SNOA has a market cap of 2.3M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while SNOA trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas SNOA's P/E ratio is -1.14. In terms of profitability, ALVOW's ROE is +0.77%, compared to SNOA's ROE of -0.46%. Regarding short-term risk, ALVOW is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check SNOA's competition here
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
ALVOW vs SXTC Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, SXTC has a market cap of 2.2M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while SXTC trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas SXTC's P/E ratio is 1.47. In terms of profitability, ALVOW's ROE is +0.77%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, ALVOW is less volatile compared to SXTC. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check SXTC's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
ALVOW vs RDHL Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, RDHL has a market cap of 2M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while RDHL trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas RDHL's P/E ratio is 0.13. In terms of profitability, ALVOW's ROE is +0.77%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, ALVOW is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check RDHL's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
ALVOW vs PROCW Comparison August 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 2B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, ALVOW is priced at $0.22 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 32.08, whereas PROCW's P/E ratio is N/A. In terms of profitability, ALVOW's ROE is +0.77%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, ALVOW is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check PROCW's competition here